Blogs

Sutherland Global Services
Sutherland Global Services Sutherland Global Services Sutherland Global Services

How important it is to detect a disease early on to get it treated effectively? Very. And you do not need a doctor to offer this piece of wisdom. As such, testing techniques are becoming an important weapon for healthcare professionals worldwide in their crusade against increasing diseases. In Vitro Diagnostics (IVD) is one such innovative weapon that is showing promise in detecting and confirming the presence of a disease, ranging from acute to lethal diseases such as cancer and Human Immunodeficiency Virus (HIV). Today, approximately 60% of all medical diagnoses are based on IVD tests.

Commonly known as ‘laboratory tests’, IVD involves testing of samples (e.g. blood, urine, tissue and other body fluids from the human body) in order to detect a wide range of infections, diseases and conditions. It can be as simple as performing a glucose test at home, or require a sophisticated technology to detect complex virus strains such as HIV and Middle East Respiratory Syndrome (MERS) at a state-of-the-art hospital.

 

 

 

Given its rising importance, the global market for IVD is expected to increase from US$ 60.3 billion in 2015 to US$ 81.1 billion in 2020, at a CAGR of 6.1%. Developed regions like North America and Europe are expected to witness a fall in their market share to 54% in 2020 from 65% in 2014 as the LAAM (Latin America, Africa and Middle East) and Asia regions jostle for a bigger market share.

Region wise, the GCC is likely to become one of the fastest-growing IVD markets during this period. This growth in the GCC IVD market will arise from higher investments in healthcare from both the government and the private sector, rising number of expatriates, growing demand for health insurance, and increasing incidences of lifestyle diseases as a result of high disposable income.

Boom times are ahead for the GCC IVD market, thanks to intense research, which would lead to a surge in the demand for IVD tests for chronic health conditions. It will be further driven by a high demand for technologically-advanced devices for early and precise detection of diseases owing to a rapid increase in the incidences of chronic and infectious diseases. However, stringent regulatory frameworks and the lack of proper reimbursement policies might put brakes on the growth.

 

 

Saudi Arabia leads the IVD market in the GCC and is expected to register 110 million IVD-based tests annually by 2019

The GCC IVD market is dominated by Saudi Arabia, followed by the UAE. Biochemistry, hematology and hormonal tests contribute about 70% to the total diagnostics tests in Saudi Arabia; whereas biochemistry, hematology and bacteriology tests contribute about 50% to the total diagnostics tests in the UAE. Between 2014 and 2019, the IVD market in Saudi Arabia grew by 14% and is further expected to grow at over 15% to reach 110 million tests annually by 2019. On the other hand, due to its exemption of import tariffs on in vitro and diagnostic equipment, the UAE has become an attractive destination for medical devices import. Over 2011-2014, the medical devices market in the country increased at a CAGR of around 11%.

Lab-in-a-backpack: POC Diagnostics in GCC is a technology definitely worth investing in

Along with the other sectors, the global healthcare is hit by the wave of disruptive innovations. Of the many innovative technologies that have come to the fore, point-of-care testing (POCT) is one.

Quick, easy and accurate diagnosis is the need of the hour as doctors and other healthcare professionals strive to provide faster response to ensure effective patient care. In this context, POCT offers a revolutionary promise for rapid, portable, and easy-to-operate IVD testing and has the potential to expand across all care sites, ranging from hospital bed to primary care (polyclinics or medical centers) to alternative care settings such as medical camp facilities, nursing facilities, and even homes. It is also set to further disrupt centralized laboratory operations with its low turnaround time as compared to the conventional IVD testing.

Accreditation Canada defines POCT as “any testing conducted outside a lab, in a hospital, in a clinic, or by a healthcare organization providing ambulatory care. It includes testing performed at sites outside the traditional lab dedicated to medical biology, near where care is delivered to a patient. POCT results may help modify methodology for patient care.”

With its ability to supplement the functions of a central laboratory, POCT is rapidly expanding across the GCC. Over the next 5 to 10 years, the POCT market in the region is expected to grow significantly, riding on rising aging population, growing middle class with high disposable income and higher incidences of infectious and chronic diseases.

All in all, it can be said that POCT is set to find more takers in the developing and emerging markets as compared to the developed markets because of comparatively weaker penetration and lower uptake until now. Such a scenario heralds exciting times for industry players, who have the opportunity to exploit newer horizons.

The future looks bright for POCT in the GCC but it would be interesting to see how fast it can be adopted and implemented.

 

Ashish Kumar Mishra – Project Manager – Strategy, Market & Business Research
Strategy and Business Research
Leave a comment
Add comments
Explore by Category
Financial Research

Strategy & Business Research
Popular Blogs
Fintech! Cost reaper or White collar multiplier?

 
 
Testimonials View All

"Thank you very much for compiling this summary - it is a fantastic overview and saves us a lot of time. I particularly liked the quotes that you pulled from the transcripts; they were exactly what we were looking for."

Analyst, Canada-based Investment Bank

"Your model building and reconstruction is remarkable for its accuracy and speed, and you saved me several weeks of work, which I greatly appreciate."

Star Analyst, US-based Investment Bank

"Sutherland's analyst is diligent, accurate, technical and thoughtful with all of his work. He is a very thorough researcher and can find difficult statistics. He stays on top of long term projects and will continue to try to complete if unsuccessful. He continues to be a huge asset to our team."

Senior Banker, Mid-Market Investment Bank

"Sutherland's analyst is an invaluable resource to me and my team. We can count on him to generate thorough, accurate materials quickly. I am impressed with Sutherland's analysts' ability to perfectly capture what it is we were looking for, having only received limited instructions via email."

Senior Banker, Large Investment Bank

"I would like to mention that we had a really good week with 4 out of 8 meetings already reaching the "hot" category. Great progression with the type and kind of companies we are meeting with."
Keep up the hard work.

Business Development Manager, A Global Business and Financial Centre based out of the GCC

"This is a small note to say that it has been great working with you. Projects have been:
1- Delivered on time.
2- Delivered to top standards.
3- Not once there has been a delay (if there has been it has been discussed prior)
4- You have also gone beyond work hours in accommodating our special requests from time to time.
5- Particularly want to mention Fruit Trees study where your role was very key and well positioned in dealing with our "end client". This was truly outstanding.
Full marks.
We value this partnership and you have treated it beyond a client/supplier relationship.
Please keep up the good work.

Director, A leading Consulting Group in the Middle East and Africa

We have never had many policies in the database, and until recently our process was to reach out to advisors for that plan. Our Michigan team had precious few medical policies as well. I wanted to call out the Sutherland team for their amazing work in adding over a hundred new policies-not just PA forms, but fully-developed medical policies as well. Many of these were dated 2016 and earlier, so they had been missed for years.
Our Mumbai team is struggling with our conventions, working all day with Excel, and large workloads. Every plan they've pulled this month has been brand-new to them. These are plans we've researched multiple times this year alone, and they still manage to dig up all kinds of new information. This is not something we gather statistics on, but anecdotally, I've been reading a lot of new (previously-missed) policies in the last two weeks.
I'm very glad to have this kind of ingenuity on our side, enhancing our product a few plans at a time. If you've had a similar experience, I ask you to please give the Mumbai team that feedback as well.
Thanks,

Project Manager, A leading global health insights provider

Terms of Service   |    Site Map
© 2013 - 2018 Sutherland Insights. All Rights Reserved
Share Us @